Vanguard Portfolio Management’s Cartesian Therapeutics RNAC Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$641K Buy
88,880
+1,563
+2% +$13.6K ﹤0.01% 3008
2026
Q2
$910K Buy
87,317
+26,734
+44% +$198K ﹤0.01% 2984
2026
Q1
$373K Hold
60,583
– – ﹤0.01% 2984

Other funds holding RNAC

Vanguard Portfolio Management's RNAC Position: Q3 2026 in Review

Vanguard Portfolio Management increased its Cartesian Therapeutics (RNAC) stake by 1.8% in Q3 2026, buying an estimated $13.6K and bringing the position to 88,880 shares worth $641K. The position accounts for ﹤0.01% of the portfolio, ranked #3008.

Vanguard Portfolio Management first reported a position in RNAC in Q1 2026 and has held it in 3 quarters since. The position peaked at $910K in Q2 2026. 100 funds tracked by Wall St. Rank hold RNAC as of Q3 2026.

  • Vanguard Portfolio Management held 88,880 shares of Cartesian Therapeutics worth $641K as of Q3 2026.
  • Vanguard Portfolio Management bought 1,563 Cartesian Therapeutics shares in Q3 2026, an estimated $13.6K.
  • Cartesian Therapeutics made up ﹤0.01% of Vanguard Portfolio Management's portfolio in Q3 2026, its #3008 holding.
  • Vanguard Portfolio Management first reported a position in Cartesian Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Portfolio Management's Cartesian Therapeutics position peaked at $910K in Q2 2026.
  • 100 funds tracked by Wall St. Rank held Cartesian Therapeutics as of Q3 2026.

Based on Vanguard Portfolio Management's 13F filing for Q3 2026, filed 13 Nov 2026.